Grupo VIDA is a medtech distributor with 23 years of experience importing and distributing high-quality products to Brazil’s healthcare market. The company has a strong background supplying blood banks and bone marrow transplant centers, and is now expanding into organ transplantation.

“Brazil, with more than 210 million inhabitants, is an incredibly exciting market, with more than 6,500 kidney transplants performed each year across 177 centers nationwide. We’re delighted to launch this collaboration with Grupo VIDA to increase access to Glycorex’s life-saving technologies in the country,” says Carl Magnus Schultz, CEO of Glycorex Transplantation.

Glycorex’s Glycosorb ABO technology has been used worldwide since 2001 to enable more than 8,000 blood-group-incompatible transplants by selectively reducing anti-A/B antibodies in the recipient’s plasma. It is used primarily in blood-group-incompatible kidney transplants, as well as in liver, heart, lung, and stem cell transplants.